Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Bone Biologics (BBLGW) FCF Margin (2016 - 2017)

Bone Biologics (BBLGW) has disclosed FCF Margin for 2 consecutive years, with 63.86% as the latest value for Q4 2017.

  • Quarterly FCF Margin changed N/A to 63.86% in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 75.28% through Dec 2017, down 63467.0% year-over-year, with the annual reading at 2143.69% for FY2025, 172074.0% up from the prior year.
  • FCF Margin for Q4 2017 was 63.86% at Bone Biologics, up from 45.06% in the prior quarter.
  • The five-year high for FCF Margin was 814.94% in Q1 2016, with the low at 45.06% in Q3 2017.